Plant Name: Hesperocyparis goveniana var. abramsiana
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.431E-11 | 1.245E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.748E-10 | 4.228E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.241E-10 | 1.495E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.945E-09 | 7.178E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.306E-09 | 9.358E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.035E-08 | 1.187E-05 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.895E-08 | 1.719E-05 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 1.536E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.019E-06 | 6.337E-04 | PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.078E-06 | 6.522E-04 | CYP1A1, CYP1B1, HDAC2, HDAC8, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 9.507E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.811E-06 | 1.011E-03 | CYP1A1, CYP1A2, CYP1B1, HDAC2, HTT, LMNA, PKM, PTGS2, SMN1, SMN2, THPO, TSHR, TYR |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.955E-06 | 1.039E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2, RAB9A |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.443E-06 | 1.237E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HTT, LMNA, NPC1, PTGS1, PTGS2, RAB9A, TYR |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 1.446E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.283E-06 | 2.256E-03 | CYP1A1, CYP1A2, CYP1B1, HDAC2, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 2.416E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.416E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 3.514E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 5.028E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 6.828E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.841E-05 | 8.838E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.460E-10 | 8.759E-09 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.907E-07 | 7.815E-06 | ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.979E-07 | 7.815E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.176E-06 | 1.411E-05 | PKM; CYP1A2; CYP1A1; ALOX12; PTGS2; CYP2C19; CYP3A4; TYR; PTGS1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.570E-07 | 1.136E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.213E-06 | 3.611E-05 | ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.252E-06 | 6.189E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.627E-05 | 1.084E-04 | CYP1A1; CYP1B1; PTGS2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.073E-06 | 3.073E-05 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.292E-05 | 1.375E-04 | PTGS2; TSHR; PTGS1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.590E-05 | 1.958E-04 | CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.296E-05 | 2.148E-04 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.064E-03 | 4.909E-03 | HDAC2; PKM; HDAC8 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 2.139E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; TYR |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; HDAC2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PKM |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; HDAC8 |